The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | What’s new in minimal residual disease (MRD) detection in myeloma?
Joan Bladé, MD, from Hospital Clinic, Barcelona, Spain, discusses how the response assessment in myeloma is evolving at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. He speaks about new techniques, which allow a single myeloma cell to be detected among 10 million cells, and describes how the subgroup of patients which can be cured can be identified using these technologies. Prof. Bladé also highlights that MRD assessment may be valuable to determine when treatment can be safely discontinued.
